Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 3/20 | 0.40 |
| ▸ | PRKCA | P17252 | 3/20 | 0.40 |
| ▸ | PRKCH | P24723 | 3/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | MAP2 | P11137 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588222 | 0.91 | SLC6A4 (0.46) | SLC6A4HTR2ASLC6A2SLC6A3PRKCB | |
| SCHEMBL989779 | 0.82 | CYP4F2 (0.40) | SLC6A4HTR2APRKCBPRKCAPRKCH | |
| SCHEMBL1028096 | 0.80 | SLC6A4 (0.38) | SLC6A4HTR2ASLC6A2SLC6A3PARP1 | |
| SCHEMBL1028961 | 0.80 | SLC6A4 (0.43) | SLC6A4HTR2ASLC6A2SLC6A3PARP1 | |
| Dimethylamine SCHEMBL5206984 | 0.79 | KDM4E (0.39) | HTR2APRKCBPRKCAPRKCHPRKCE | |
| SCHEMBL3596009 | 0.78 | AKR1B1 (0.42) | SLC6A4HTR2ASLC6A2SLC6A3PRKCB | |
| SCHEMBL27658425 | 0.77 | RAD52 (0.44) | SLC6A4HTR2ASLC6A2SLC6A3PRKCB | |
| SCHEMBL1030722 | 0.76 | GRM2 (0.35) | SLC6A4HTR2APLA2G2A | |
| SCHEMBL856959 | 0.74 | SIRT1 (0.48) | SLC6A4HTR2AMAP2HTR7HTR2B | |
| SCHEMBL3588780 | 0.74 | CYP4F2 (0.40) | SLC6A4HTR2APRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426440-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| EP-1745037-B1 | Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases | NOVARTIS AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| EP-2246346-B1 | Indolylmaleimide derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| EP-1904482-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-2270001-A1 | Indolylmaleimide derivatives as PKC inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| CN-101933926-A | Indolylmaleimde derivatives as PKC inhibitors | NOVARTIS AG | 2011-01-05 | — | — | CN | disclosed |
| EP-2246346-A1 | Indolylmaleimide derivatives as protein kinase inhibitors | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | WAGNER JUERGEN | 2010-10-28 | — | — | US | disclosed |
| US-7781438-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| CN-1910173-B | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG | 2010-06-09 | — | — | CN | disclosed |
| US-7648989-B2 | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2010-01-19 | — | — | US | disclosed |
| US-20080318975-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| CN-1910173-A | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2007-02-07 | — | — | CN | disclosed |
| EP-1745037-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS | Novartis AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005068455-A1 | INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | IDO1, INMT, IDO2 | SLC6A4 3462/4885HTR2A 448/4885SLC6A2 4588/4885 |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | PRKCE, PRKCH, PRKCI | SLC6A4 2409/4885HTR2A 2501/4885SLC6A2 3796/4885 |
| US-20080318975-A1 | Indolylmaleimide Derivatives | IDH3A, INMT, IDH3B | SLC6A4 2812/4885HTR2A 1211/4885SLC6A2 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.